- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01438424
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
19. července 2012 aktualizováno: Bristol-Myers Squibb
A Preliminary Assessment of Safety and Antiviral Activity of Open-label Entecavir in Subjects With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
The purpose of this study is to provide entecavir to participants who have completed another entecavir trial without achieving virologic response or who relapsed during postdosing follow-up.
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Typ studie
Intervenční
Zápis (Aktuální)
1053
Fáze
- Fáze 2
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
16 let a starší (Dítě, Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Key inclusion criteria:
- Age of 16 years and older
- Receipt of entecavir or lamivudine in a previous entecavir study.
Participants who were, based on their response to entecavir:
- Virologic nonresponders at Week 48
- Partial virologic responders who became nonresponders during the second year of treatment
- Partial virologic responders at Week 96
Complete responders who relapsed during postdosing follow-up
- Decompensated liver disease in AI463-048 that met 1 or more of the following criteria:
- Nonresponse to adefovir after at least 24 weeks of treatment
- Partial response to adefovir after 96 weeks of treatment
- Complete response to adefovir after relapsing during postdosing follow-up
Demonstrated intolerance to adefovir
- Except for those participants enrolled from AI463-048, compensated liver disease.
Key exclusion criteria:
- HIV coinfection
- Receiving nephrotoxic or hepatotoxic agents
- Ongoing opportunistic infections
- Hemoglobin level <11.0 g/dL except for those enrolled from AI463-048
- Platelet count <70,000 mm^3 except for those enrolled from AI463-048
- Absolute granulocyte count <1,500 cells/mm^3
- Recent history of pancreatitis (within 24 weeks prior to first dose of therapy)
- Current evidence of ascites requiring paracentesis, hepatic encephalopathy, or variceal bleeding, except for those enrolled from AI463-048
- Known history of allergy to nucleoside analogues.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Entecavir, 1.0 mg, with or without lamivudine
|
Tablets, Oral, 1.0 mg, once daily
Ostatní jména:
Oral, 100 mg, daily
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Overall Study: Number of Participants With Death As Outcome, Any Adverse Event (AE), Grade 3-4 AEs, Serious Adverse Events (SAEs), and Discontinuations Due to AEs
Časové okno: Continuously from Day 1 through Week 240
|
An AE is a new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not be causally related to treatment.
An SAE is an unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling.
ALT=alanine transaminase; ULN=upper limit of normal.
|
Continuously from Day 1 through Week 240
|
Overall Study: Number of Participants With Normal Hematology Values at Baseline and Abnormalities in Hematology Laboratory Test Results Through Week 240
Časové okno: Day 1 of treatment through Week 240
|
Hemoglobin (g/dL): Grade (Gr) 1=9.5-11.0;
Gr 2=8.0-<9.5;
Gr 3=6.5-<8.0;
Gr 4=<6.5 White blood cells (cells/mm^3): Gr 1=2,500-<4,000; Gr 2=1,000-<2,500; Gr 3=800-<1,000; Gr 4=<800.
Neutrophils (cells/mm^3): Gr 1=1000-<1500; Gr 2=750-<1000; Gr 3=500-<750; Gr 4=<500.
Platelets (cells/mm^3): Gr 1=75,000-99,000; Gr 2=50,000-<75,000; Gr 3=20,000-<50,000; Gr 4=<20,000.
Prothrombin time (seconds): Gr 1=1.01-<1.26*ULN;
Gr 2=1.26-<1.51
*ULN; Gr 3=1.51-3*ULN;
Gr 4=>3*ULN.
INR: Gr 1=1.24-1.5;
Gr 2=1.5-2;
Gr 3=2-3; Gr 4=>3.
INR=international normalized ratio; ULN=upper limit of normal. .
|
Day 1 of treatment through Week 240
|
Overall Study: Number of Participants With Normal Pancreatic Enzyme and Renal Function Values at Baseline and Abnormalities in Pancreatic Enzyme and Renal Function Laboratory Test Results at End of Dosing
Časové okno: Day 1 of treatment through Week 240
|
Amylase: Grade 1=1.10-<1.40*ULN;
Grade 2=1.40-< 2.10*ULN; Grade 3=2.10-5.00*ULN;
Grade 4=>5.00*ULN.
Lipase: Grade 1.1-<1.4*ULN;
Grade 2=1.4-<2.1*ULN;
Grade 3=2.1-5.0*ULN;
Grade 4=>5.0*ULN.
Creatinine: Grade 1=1.10-< 1.60*ULN; Grade 2=1.60-<3.10*ULN;
Grade 3=3.10-6.00*ULN;
Grade 4=>6.00*ULN.
Blood urea nitrogen (BUN): Grade 1=1.25-<2.60*ULN;
Grade 2=2.60-<5.10*ULN;
Grade 3=5.10-10*ULN;
Grade 4=>10*ULN.
ULN=upper limit of normal.
|
Day 1 of treatment through Week 240
|
Overall Study: Number of Participants With Normal Electrolyte and Fasting Glucose Values at Baseline and Abnormalities in Electrolyte and Fasting Glucose Laboratory Test Results at End of Dosing
Časové okno: Day 1 of treatment through Week 240
|
Hypochloremia: Grade (Gr) 1=90-93; Gr 2=85-<90; Gr 3=80-<85; Gr 4=40-<80.
Hyperchloremia: Gr 1=113-<117; Gr 2=117-<121; Gr 3=121-125; Gr 4>125.
Hypocarbia: Gr 1=19-21; Gr 2=15-<19; Gr 3=41-45; Gr 4=>45.
Hypercarbia: Gr 1=31-36; Gr 2=37-40; Gr 3=41-45; Gr 4=>45.
Hyponatremia: Gr 1=130-132; Gr 2=123-<130; Gr 3=116-<123; Gr 4<116.
Hypernatremia: Gr 1=148-<151; Gr 2=151-<158; Gr 3=158-165; Gr 4=>165.
Hypokalemia: Gr 1=3-3.4;
Gr 2=2.5-<3;
Gr 3=2-<2.5;
Gr 4=<2.
Hyperkalemia: Gr 1=5.6-<6.1;
G2=6.1-<6.6;
Gr 3=6.6-7;
Gr 4=>7.
Hypoglycemia: Gr 1=55-64; Gr 2=40-<55; Gr 3=30-< 40; G4=-<30.
Hyperglycemia: Gr 1=116-<161; Gr 2=161-<251; Gr 3=251-500; Gr 4>500.
|
Day 1 of treatment through Week 240
|
Week 144: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
Časové okno: Continuously from Day 1 through Week 144
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment.
An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling.
AST=aspartate aminotransferase; ULN=upper limit of normal.
|
Continuously from Day 1 through Week 144
|
Week 192: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
Časové okno: Continuously from Day 1 through Week 192
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment.
An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
CTC Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling.
ALT=alanine aminotransferase; ULN=upper limit of normal.
|
Continuously from Day 1 through Week 192
|
Off-treatment Follow-up: Percentage of Participants With Sustained Hepatitis B Virus (HBV) DNA <10,000 Copies by Polymerase Chain Reaction (PCR) Assay (Amendment 11 Cohort)
Časové okno: End of dosing to Week 48 off-treatment follow-up
|
The Amendment 11 Cohort consisted of participants who were hepatitis B e antigen (HBeAg) negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA <300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0*ULN at the end of study drug dosing.ALT=alanine aminotransferase; ULN=upper limit of normal.
|
End of dosing to Week 48 off-treatment follow-up
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Overall Study: Percentage of Participants With Sustained HBV DNA Level <300 Copies/mL by PCR Assay
Časové okno: Study entry to Week 192
|
Study entry to Week 192
|
|
Overall Study: Percentage of Participants With Sustained HBV DNA <10^4 Copies/mL by PCR Assay
Časové okno: Study entry to Week 192
|
Study entry to Week 192
|
|
Overall Study: Percentage of Participants by HBV DNA Category by PCR Assay
Časové okno: Baseline to Week 192
|
Observed values.
|
Baseline to Week 192
|
Overall Study: Mean HBV DNA Level by PCR Assay
Časové okno: Study entry to Week 216
|
Study entry to Week 216
|
|
Overall Study: Percentage of Participants Who Achieved a Loss of Hepatitis B e Antigen (HBeAg)
Časové okno: Study entry to Week 216
|
Observed values.
|
Study entry to Week 216
|
Overall Study: Percentage of Participants With HBeAg Seroconversion
Časové okno: Study entry to Week 216
|
Observed values.
Seroconversion=negative HBeAg with detectable anti-HBe antibody.
|
Study entry to Week 216
|
Overall Study: Mean Alanine Transaminase (ALT) Levels
Časové okno: Study entry to Week 216
|
Observed values.
|
Study entry to Week 216
|
Overall Study: Percentage of Participants Who Achieved ALT Normalization
Časové okno: Study entry to Week 216
|
ULN=upper limit of normal.
ALT normalization=ALT levels ≤1.0*ULN.
|
Study entry to Week 216
|
Week 192: Percentage of Participants With Histologic Improvement (Efficacy Evaluable Cohort)
Časové okno: Baseline to Week 192
|
The Knodell Histologic Activity Index scores stage of necrosis and grade of inflammation in liver biopsies.
Components are necrosis near the portal vein, intralobular degeneration and focal necrosis, portal inflammation, and fibrosis.
The 4 components are scored from 1 to 4 and 1 to 10 (necrosis near the portal vein) and combined for a total score, with 22 being the highest possible score.
Higher the score for each component=greater liver damage.
Histologic improvement=a ≥2-point reduction in total Knodell score and no worsening in fibrosis.
Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell necroinflammatory scores ≥2.
|
Baseline to Week 192
|
Week 192: Percentage of Participants With Improvement in Fibrosis (Efficacy Evaluable Cohort)
Časové okno: Baseline to Week 192
|
The Ishak Modification for Hepatic Activity Index (HAI) scores necroinflammatory activity in chronic hepatitis.
0=no fibrosis, 1=fibrosis expansion of some portal areas, 2=fibrosis expansion of most portal areas, 3=fibrosis expansion of most portal areas with occasional bridging, 4=fibrosis expansion of portal areas with marked bridging, 5=incomplete cirrhosis, 6=probable or definite cirrhosis.
Higher score=more severe necrosis.
Improvement in fibrosis=≥1-point reduction in HAI score.
Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell scores ≥2.
|
Baseline to Week 192
|
Overall Study: Percentage of Participants With a Confirmed ≥1 log10 Increase From Nadir in HBV DNA by PCR Assay
Časové okno: Baseline to Week 144
|
Baseline to Week 144
|
|
Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAG, Seroconversion, and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Continuous Treatment Cohort)
Časové okno: Baseline to Weeks 48, 96, 144, 192, and 240
|
The Entecavir Continuous Treatment Cohort consisted of participants from study AI463-022 (NCT00035633) who were nucleoside-naive HBeAg-positive and enrolled in the current study with ≤35 days off treatment between the last dose in AI463-022 and the first dose in the current.
This cohort is considered to be on continuous entecavir treatment and permitted assessment of continuous administration of entecavir in AI463-022 and the current study.
|
Baseline to Weeks 48, 96, 144, 192, and 240
|
Percentage of Participants Who Achieved HBV DNA <300 and <10^4 Copies/mL by PCR Assay and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Retreatment Cohort)
Časové okno: Baseline to Weeks 48, 96, and 144
|
The Entecavir Retreatment Cohort consisted of participants who were nucleoside-naive, HBeAg-negative and enrolled from BMS study AI463-027 with >60 days off treatment between the last dose in AI463-027 and the first dose in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as retreatment in the current study.
|
Baseline to Weeks 48, 96, and 144
|
Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAg, HBeAg Seroconversion, and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
Časové okno: Baseline to Week 96
|
The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
|
Baseline to Week 96
|
Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
Časové okno: Baseline to Week 144
|
The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
|
Baseline to Week 144
|
Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
Časové okno: Baseline to Week 96
|
The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with >60 days between end of dosing in AI463-027 and the switch to entecavir in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
|
Baseline to Week 96
|
Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
Časové okno: Baseline to Week 144
|
The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with >60 days between end of dosing in AI463-027 and the switch to entecavir in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
|
Baseline to Week 144
|
Off-treatment Follow-up: Percentage of Participants With Sustained HBV DNA <1,000, <300, and <10,000 Copies/mL by PCR Assay and With ALT ≤1*ULN (Amendment 11 Cohort)
Časové okno: End of dosing to Weeks 48 and 96 off-treatment follow-up
|
The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA <300 copies/mL by PCR Assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0*ULN at the end of study drug dosing.
ULN=upper limit of normal.
|
End of dosing to Weeks 48 and 96 off-treatment follow-up
|
Off-treatment Follow-up: Mean Change in HBV DNA (Amendment 11 Cohort)
Časové okno: End of dosing to Weeks 48 and 96 off-treatment follow-up
|
The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA <300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0*ULN at the end of study drug dosing.
|
End of dosing to Weeks 48 and 96 off-treatment follow-up
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. ledna 2001
Primární dokončení (Aktuální)
1. prosince 2009
Dokončení studie (Aktuální)
1. dubna 2011
Termíny zápisu do studia
První předloženo
16. září 2011
První předloženo, které splnilo kritéria kontroly kvality
21. září 2011
První zveřejněno (Odhad)
22. září 2011
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
23. srpna 2012
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
19. července 2012
Naposledy ověřeno
1. července 2012
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Nemoci trávicího systému
- RNA virové infekce
- Virová onemocnění
- Infekce
- Infekce přenášené krví
- Přenosné nemoci
- Onemocnění jater
- Hepatitida, virová, lidská
- Infekce Hepadnaviridae
- DNA virové infekce
- Enterovirové infekce
- Infekce Picornaviridae
- Hepatitida, chronická
- Žloutenka typu B
- Hepatitida
- Žloutenka typu A
- Hepatitida B, chronická
- Molekulární mechanismy farmakologického působení
- Antiinfekční látky
- Antivirová činidla
- Inhibitory reverzní transkriptázy
- Inhibitory syntézy nukleových kyselin
- Inhibitory enzymů
- Anti-HIV činidla
- Antiretrovirová činidla
- Entecavir
- Lamivudin
Další identifikační čísla studie
- AI463-901
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HBV
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Duke-NUS Medical School (Singapore)NáborHBV | HBV/HDVItálie
-
Centre de Recherches et d'Etude sur la Pathologie...Dokončeno
-
Aucta Pharmaceuticals, IncDokončeno
-
The First Hospital of Jilin UniversityNeznámý
-
Institute of Liver and Biliary Sciences, IndiaStaženo
-
Yi-Hua ZhouThe First People's Hospital of Kunshan; Taixing People's Hospital; Fourth People... a další spolupracovníciDokončeno
-
West China HospitalNáborTransplantace ledvin | HBVČína
-
Fudan UniversityAktivní, ne náborHBV | TRANSPLANTACE JATERČína
-
RenJi HospitalZatím nenabírámeHBV | Porucha transplantace jater
-
Kaohsiung Medical University Chung-Ho Memorial...Nábor
Klinické studie na Entecavir
-
ShuGuang HospitalBeijing YouAn Hospital; Beijing Ditan Hospital; Shanghai Zhongshan Hospital; Tongji... a další spolupracovníciNeznámýCirhóza jater způsobená virem hepatitidy BČína
-
ShuGuang HospitalShanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Public Health Clinical... a další spolupracovníciNeznámý
-
National Taiwan University HospitalNeznámýKoinfekce HBV/HCVTchaj-wan
-
Sun Yat-sen UniversityNeznámý
-
Sun Yat-sen UniversityNeznámý
-
Hanmi Pharmaceutical Company LimitedNeznámýChronická hepatitida BKorejská republika
-
The University of Hong KongNáborTransplantace jater; Komplikace | Okultní hepatitida BHongkong
-
Taipei Veterans General Hospital, TaiwanChina Medical University Hospital; Chang Gung Memorial Hospital; Changhua Christian...NeznámýChronická hepatitida B
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NeznámýChronická hepatitida BČína
-
Bristol-Myers SquibbDokončenoHepatitida B, chronickáArgentina, Francie, Itálie, Korejská republika, Tchaj-wan, Spojené státy, Španělsko, Austrálie, Brazílie